SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$41.71 USD
+0.78 (1.91%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $41.73 +0.02 (0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum D VGM
Company Summary
Stamford, CT-based SpringWorks Therapeutics, Inc. uses a precision medicine approach to develop medicines for severe rare diseases, including rare tumor types and genetically defined cancers.
SpringWorks’ oral gamma-secretase inhibitor, Ogsiveo (nirogacestat), was approved by the FDA for treating adult patients with progressing desmoid tumors who require systemic treatment in November 2023. Ogsiveo is the first approved product in the company’s portfolio. It is also the first approved drug for desmoid tumors.
The European Medicines Agency (EMA) validated the marketing authorization application (MAA) for Ogsiveo ...
Company Summary
Stamford, CT-based SpringWorks Therapeutics, Inc. uses a precision medicine approach to develop medicines for severe rare diseases, including rare tumor types and genetically defined cancers.
SpringWorks’ oral gamma-secretase inhibitor, Ogsiveo (nirogacestat), was approved by the FDA for treating adult patients with progressing desmoid tumors who require systemic treatment in November 2023. Ogsiveo is the first approved product in the company’s portfolio. It is also the first approved drug for desmoid tumors.
The European Medicines Agency (EMA) validated the marketing authorization application (MAA) for Ogsiveo for the treatment of adult patients with desmoid tumors in February 2024.
SpringWorks is also evaluating Ogsiveo as a monotherapy and in combination therapy for other cancer indications.
In July 2024, SpringWorks completed the rolling new drug application (NDA) submission process with the FDA for mirdametinib, an oral, small molecule MEK inhibitor, developed for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a rare tumor of the peripheral nerve sheath that causes significant pain and disfigurement.
The company plans to file an MAA with the EMA for mirdametinib in NF1-PN in the European Union later in the second half of 2024.
SpringWorks is evaluating its other candidate, brimarafenib (BGB-3245), in various early-stage studies in combination therapies for treating colorectal and pancreatic cancer as well as certain mutant solid tumors.
SpringWorks’ top line currently comprises sales of its newly approved drug, Ogsiveo and other revenues. In 2023, the company recorded total revenues of $5.4 million, comprising sales of Ogsiveo.
General Information
SpringWorks Therapeutics
100 WASHINGTON BOULEVARD
STAMFORD, CT 06902
Phone: 203-883-9490
Fax: NA
Web: http://www.springworkstx.com
Email: investors@springworkstx.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.75 |
Current Year EPS Consensus Estimate | -3.34 |
Estimated Long-Term EPS Growth Rate | 32.80 |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 40.93 |
52 Week High | 53.92 |
52 Week Low | 18.00 |
Beta | 0.79 |
20 Day Moving Average | 938,745.12 |
Target Price Consensus | 66.00 |
4 Week | 24.77 |
12 Week | 3.70 |
YTD | 14.27 |
4 Week | 18.10 |
12 Week | -1.83 |
YTD | -3.50 |
Shares Outstanding (millions) | 74.27 |
Market Capitalization (millions) | 3,097.93 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 56.80% |
vs. Previous Quarter | 54.24% |
vs. Previous Year | NA% |
vs. Previous Quarter | 184.36% |
Price/Book | 5.55 |
Price/Cash Flow | NA |
Price / Sales | NA |
6/30/24 | -56.13 |
3/31/24 | -66.48 |
12/31/23 | -65.69 |
6/30/24 | -48.80 |
3/31/24 | -57.28 |
12/31/23 | -57.04 |
6/30/24 | 7.91 |
3/31/24 | 6.85 |
12/31/23 | 6.41 |
6/30/24 | 7.77 |
3/31/24 | 6.77 |
12/31/23 | 6.37 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | -349.32 |
3/31/24 | -1,281.78 |
12/31/23 | -5,968.50 |
6/30/24 | 7.51 |
3/31/24 | 7.66 |
12/31/23 | 10.01 |
6/30/24 | 1.02 |
3/31/24 | 0.78 |
12/31/23 | 0.54 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |